All News
TICOPA Study: Tight Control in Psoriatic Arthritis
Tight control in rheumatoid arthritis was introduced with the TICORA trial and validated in numerous treat-to-target studies since. Now the benefits of tight control in psoriatic arthritis (PsA) have been reported.
Read ArticleDSB: Drug Shortages - September 2015
RheumNow is committed to reporting safety issues in our monthly Drug Safety Bulletins. Each month we will update you with reports of new, ongoing and resolved Drug Shortages that will affect the practicing rheumatologist.
Read ArticleACR/SPARTAN 2015 Recommendations for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
The ACR and SPARTAN (Spondyloarthritis Research and Treatment Network) has worked together to study 57 specific treatment questions regarding AS and SpA. The following guidelines have recently been published after conducting systematic literature reviews.
Read ArticleDr. Woodcock Gives Senate FDA Update on Biosimilars
Biologics have been a great advance in therapeutics, but at great cost. Although biologics account for less than 1% of all prescriptions in the USA, they account for 28% percent of the cost of prescribed medications.
Read ArticleBiosimilar SB4 Performs Equally to Etanercept
Biosimilars are rapidly growing. Many of these will have their first introduction to countries outside of the USA. There is concern whether biosimilars will provide identical pharmacodynamics, biological function, efficacy and toxicity to reference products, both in the short and long term.
Read ArticlePLLR - The Pregnancy & Lactation Labeling Rule Explained
A recent article from Healio.com reviewed the FDA’s Pregnancy and Lactation Labeling Rule (PLLR) that became effective June 30th.
Read ArticleFuture 2 Trial Shows Secukinumab Efficacy in Psoriatic Arthritis
Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis. It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.
Read ArticleDAS28-CRP or DAS28-ESR: Are they Biosimilar?
The disease activity score (DAS28) has been developed as a dynamic assessment tool and a therapeutic response measure for use in clinical trials and practice.
Read ArticleNew Drugs, New Hope for Pulmonary Fibrosis
The Wall Street Journal reports that new drug development offers hope for people with idiopathic pulmonary fibrosis, a rare, progressive fibrosing lung disorder that affects nearly 200,000 Americans, mostly middle-aged and older adults.
Read ArticleGouty Tomatoes, Alveolar Hemorrhage and Famous RA Faces: August 2015 Top Social Media News
In August, RheumNow published 76 tweets covering novel news, research and teaching points gleaned from the medical literature, regulatory reports and internet sources. We had a reach (impressions) of 60,800, with 45 mentions, and 2049 visits to RheumNow.com.
Read ArticleA Controlled Trial of Yoga Benefits Arthritis Patients
Yoga and stretching appear to be important forms of exercise for patients with fibromyalgia, but their utility has seldom been explored in patients with rheumatoid or osteoarthritis.
Read ArticleCan Fibromyalgia in Children be Treated Without Medication?
The hallmarks of fibromyalgia -- widespread pain, poor sleep, effort intolerance, fatigue -- are difficult to manage and usually require medication and a multi-modal approach.
Read ArticleMonitoring of Novel Therapies in Rheumatology
The rheumatology therapeutic landscape has changed almost yearly in the last 15 years, with the introduction of at least 16 biologic or novel agents for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), spondyloarthritis (SpA), juvenile arthritis,
Read ArticleAdalimumab FDA Approved for Hidradenitis Suppurativa
Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.
Read ArticleJIA Pathogenesis Related to Neutrophils and Epigenetics
Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).
Read ArticleEducation of the Fibromyalgia Patient
This week's Daily Download is the fibromyalgia “packet” we give to our patients once they have been diagnosed with fibromyalgia.
Read ArticleDrug Safety Reports & FDA Updates – August 2015
Safety reports from literature include long-term safety of rituximab, rituximab-induced neutropenia, tabalumab (Anti-BAFF Mab) results from the ILLUMINATE trial, colchicine toxicity increased in CKD patients, FDA updates and drug labeling changes, and more.
Read ArticleSerious Infections Increased in Etanercept-Treated Juvenile Arthritis Patients
UK researchers set out to study medically significant infections (MSI) in juvenile idiopathic arthritis patients enrolled in the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN).
Read ArticleMore Knee Replacements at Younger Ages
The National Hospital Discharge Survey shows that between 2000 and 2010, more than 5.2 million total knee replacements were performed in the United States. By 2010, the operation had become the leading inpatient surgery performed on adults aged 45 and over.
Read ArticleSCOT Study Shows NSAID Safety
Since the 2005 FDA hearing that resulted in the removal of Vioxx and Bextra from the US market, the safety of nonselective NSAIDs (nsNSAIDs) and selective Cox-2 inhibitors (e.g., celecoxib) has been repeatedly questioned, often without new or substantive data.
Read Article